TURKU, FINLAND / ACCESS Newswire / March 21, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)(AIM: FARN) (First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach ...

Sanofi SA is getting deeper into oncology and immunology therapy development through buying Dren Bio Inc.’s myeloid cell engager for deep B-cell depletion, DR-0201. The deal could reach as high as $1.

CERo’s technology works by grafting onto patients’ own T-cells a receptor that binds to a naturally occurring human antigen ...

Sanofi’s move for Dren Bio’s clinical asset boosts its immunology-focused strategy of becoming a leader in the field.

The deal with startup Dren Bio hands Sanofi a so-called myeloid cell engager that would compete with an array of programs ...

Sanofi is set to acquire DR-0201 from Dren Bio for up to $1.9 billion, aiming to expand its autoimmune disease pipeline with ...

Sanofi (SNY) and Dren Bio, a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has ...

In the latest move to cement its “immunology powerhouse” status, Sanofi is handing ove | The CD20-directed antibody, dubbed ...

The following is a summary of “Improved survival in older patients with myeloid malignancies undergoing haploidentical ...

Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipelineDren Bio deep B-cell ...

Sanofi said it would acquire Bispecific Myeloid Cell Engager, an autoimmune disease treatment, from Dren Bio, for up to $1.9 billion.

Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...